Inflation Reduction Act's out-of-pocket cap lowered insulin costs, improved usage for some patients

Article excerpt

Medicare beneficiaries who hit the Inflation Reduction Act's $35 insulin cap did use more insulin and paid less out of pocket, a new JAMA study found. But the policy's real-world impact proved narrow: only a small slice of U.S. patients actually benefited. The finding highlights a gap between the law's ambitions and its reach, a reminder that even well-intentioned price caps can fail to help most people who need them.